Log In
Print
BCIQ
Print
Print this Print this
 

tecemotide (L-BLP25) (formerly Stimuvax)

Also known as: BLP25 liposome vaccine

  Manage Alerts
Collapse Summary General Information
Company Oncothyreon Inc.
DescriptionLiposomal vaccine containing a synthetic 25 amino acid peptide sequence from mucin 1 (MUC1; CD227)
Molecular Target Mucin 1 (MUC1) (CD227)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat stage IIIB and IV non-small cell lung cancer (NSCLC); Treat stage lll non-small cell lung cancer (NSCLC); Treat unresectable, locally advanced stage III non-small cell lung cancer (NSCLC)
Regulatory Designation

Partner

Merck KGaA; Ono Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today